Treatment with a Uroselective α1-Blocker Improves Voiding and Sexual Function: A Study in Thai Men with Lower Urinary Tract Symptoms

Journal of Sexual Medicine

Volumn 8, Issue 9, 2011, Pages 2582-2589

  Permpongkosol, Sompol ^a   Krilad O Larn, Santichai ^a   Ratana O Larn, Krisada ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Alfuzosin; Benign Prostatic Hyperplasia; Lower Urinary Tract Symptoms; Sexual Dysfunction; Uroselective Alpha 1 Blocker

Indexed keywords

ALFUZOSIN;

ADULT; AGED; ARTICLE; DIZZINESS; DRUG SAFETY; DRUG WITHDRAWAL; ERECTILE DYSFUNCTION; FOLLOW UP; HUMAN; INTERNATIONAL INDEX OF ERECTILE FUNCTION; INTERNATIONAL PROSTATE SYMPTOM SCORE; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; MALE SEXUAL DYSFUNCTION; MICTURITION; MONOTHERAPY; ORGAN SIZE; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; PROSTATE; RETROSPECTIVE STUDY; SEXUAL FUNCTION;

EID: 80052501431     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2011.02359.x     Document Type: Article

References (29)

1. Seftel AD, Rosen RC, Rosenberg MT, Sadovsky R. Benign prostatic hyperplasia evaluation, treatment and association with sexual dysfunction: Practice patterns according to physician specialty. Int J Clin Pract 2008;62:614-22.
2. Ishizu H, Yokota T, Moriyama K, Yoshida N, Onaka Y. Definition and diagnostic criteria of psychogenic erectile dysfunction. Nippon Rinsho 2002;60(suppl 6):431-8.
3. Lizza EF, Rosen RC. Definition and classification of erectile dysfunction: Report of the Nomenclature Committee of the International Society of Impotence Research. Int J Impot Res 1999;11:141-3.
4. Speakman MJ. PDE5 inhibitors in the treatment of LUTS. Curr Pharm Des 2009;15:3502-5.
5. Rosen R, Altwein J, Boyle P, Kirby RS, Lukacs B, Meuleman E, O'Leary MP, Puppo P, Robertson C, Giuliano F. Lower urinary tract symptoms and male sexual dysfunction: The multinational survey of the aging male (MSAM-7). Eur Urol 2003;44:637-49.
6. Sells H, Donovan J, Ewings P, MacDonagh RP. The development and validation of a quality-of-life measure to assess partner morbidity in benign prostatic enlargement. BJU Int 2000;85:440-5.
7. Kaplan SA, Gonzalez RR, Te AE. Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. Eur Urol 2007;51:1717-23.
8. Permpongkosol S, Kongkakand A, Ratana-Olarn K, Tantiwong A, Tantiwongse K. Increased prevalence of erectile dysfunction (ED): Results of the second epidemiological study on sexual activity and prevalence of ED in Thai males. Aging Male 2008;11:128-33.
9. Miner M, Rosenberg MT, Perelman MA. Treatment of lower urinary tract symptoms in benign prostatic hyperplasia and its impact on sexual function. Clin Ther 2006;28:13-25.
10. AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J Urol 2003;170:530-47.
11. Kuritzky L, Rosenberg MT, Sadovsky R. Efficacy and safety of alfuzosin 10mg once daily in the treatment of symptomatic benign prostatic hyperplasia. Int J Clin Pract 2006;60:351-8.
12. Gur S, Sikka SC, Chandra S, Koka PS, Agrawal KC, Kadowitz PJ, Hellstrom WJ. Alfuzosin attenuates erectile dysfunction in rats with partial bladder outlet obstruction. BJU Int 2008;102:1651-7.
13. Leungwattanakij S, Watanachote D, Noppakulsatit P, Petchpaibuol T, Choeypunt N, Tongbai T, Wanamkang T, Lojanapiwat B, Permpongkosol S, Tantiwong A, Pripatnanont C, Akarasakul D, Kongwiwatanakul S, Chotikawanich E. Sexuality and management of benign prostatic hyperplasia with alfuzosin: SAMBA Thailand. J Sex Med 2010;7:3115-26.
14. Rhoden EL, Teloken C, Sogari PR, Vargas Souto CA. The use of the simplified International Index of Erectile Function (IIEF-5) as a diagnostic tool to study the prevalence of erectile dysfunction. Int J Impot Res 2002;14:245-50.
15. MacDonald KG, Jr. Overview of the epidemiology of obesity and the early history of procedures to remedy morbid obesity. Arch Surg 2003;138:357-60.
16. Shiwaku K, Anuurad E, Enkhmaa B, Kitajima K, Yamane Y. Appropriate BMI for Asian populations. Lancet 2004;363:1077.
17. Kushiro T, Takahashi A, Saito F, Otsuka Y, Soma M, Kurihara T, Satomura A, Saito T, Kanmatsuse K. Erectile dysfunction and its influence on quality of life in patients with essential hypertension. Am J Hypertens 2005;18:427-30.
18. Van Moorselaar RJ, Hartung R, Emberton M, Harving N, Matzkin H, Elhilali M, Alcaraz A, Vallancien G, ALF-ONE Study Group. Alfuzosin 10 mg once daily improves sexual function in men with lower urinary tract symptoms and concomitant sexual dysfunction. BJU Int 2005;95:603-8.
19. El-Sakka AI. Lower urinary tract symptoms in patients with erectile dysfunction: Analysis of risk factors. J Sex Med 2006;3:144-9.
20. Jung JH, Jae SU, Kam SC, Hyun JS. Correlation between Lower Urinary Tract Symptoms (LUTS) and sexual function in benign prostatic hyperplasia: Impact of treatment of LUTS on sexual function. J Sex Med 2009;6:2299-304.
21. Rosen RC, Fitzpatrick JM. Ejaculatory dysfunction in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. BJU Int 2009;104:974-83.
22. Nickel JC, Elhilali M, Emberton M, Vallancien G. The beneficial effect of alfuzosin 10 mg once daily in "real-life" practice on lower urinary tract symptoms (LUTS), quality of life and sexual dysfunction in men with LUTS and painful ejaculation. BJU Int 2006;97:1242-6.
23. Palea S, Barras M. Comparison of the relaxant effects of alfuzosin, phentolamine and sildenafil on rabbit isolated corpus cavernosum. BJU Int 2003;91:873-7.
24. Mayoux E, Ramirez JF, Pouyet T, Barras M, Arbilla S, Galzin AM. Alfuzosin improves penile erection triggered by apomorphine in spontaneous hypertensive rats. Eur Urol 2004;45:110-6; discussion 16.
25. Oger S, Behr-Roussel D, Gorny D, Charles Tremeaux J, Combes M, Alexandre L, Giuliano F. Combination of alfuzosin and tadalafil exerts in vitro an additive relaxant effect on human corpus cavernosum. J Sex Med 2008;5:935-45.
26. Liguori G, Trombetta C, De Giorgi G, Pomara G, Maio G, Vecchio D, Ocello G, Ollandini G, Bucci S, Belgrano E. Efficacy and safety of combined oral therapy with tadalafil and alfuzosin: An integrated approach to the management of patients with lower urinary tract symptoms and erectile dysfunction. Preliminary report. J Sex Med 2009;6:544-52.
27. Hartung R, Matzkin H, Alcaraz A, Emberton M, Harving N, van Moorselaar J, Elhilali M, Vallancien G, ALF-ONE Study Group. Age, comorbidity and hypertensive co-medication do not affect cardiovascular tolerability of 10 mg alfuzosin once daily. J Urol 2006;175:624-8.
28. Rosen R, Seftel A, Roehrborn CG. Effects of alfuzosin 10 mg once daily on sexual function in men treated for symptomatic benign prostatic hyperplasia. Int J Impot Res 2007;19:480-5.
29. Shimizu F, Taguri M, Harada Y, Matsuyama Y, Sase K, Fujime M. Impact of dry ejaculation caused by highly selective alpha1A-blocker: Randomized, double-blind, placebo-controlled crossover pilot study in healthy volunteer men. J Sex Med 2010;7:1277-83.